Find disease awareness content and relevant supporting materials

Areas covered: This article reviews the clinical efficacy and safety of oral and intravenous lasmiditan as a possible acute migraine treatment. We analyze all currently available results in Phase I to III studies.

Objective: To incorporate recent research findings, expert consensus, and patient perspectives into updated guidance on the use of new acute and preventive treatments for migraine in adults.

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

Eli Lilly and Company has announced the submission of a New Drug Application (NDA) to the FDA for lasmiditan for...

Eli Lilly and Company and CoLucid Pharmaceuticals announced an agreement for Lilly to acquire CoLucid for $46.50 per share or...

he primary aim of the present Consensus was to provide a definition of triptan failure. To develop this definition, we deemed necessary to develop as first a consensus definition of effective treatment of an acute migraine attack and of triptan-responder.

Eli Lilly and Company announced that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its...

The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.

Migraine is a common and highly disabling neurological disorder associated with a high socioeconomic burden. Effective migraine management depends on adequate patient education: to avoid unrealistic expectations, the condition must be...

CoLucid Pharmaceuticals provided additional data regarding onset of action demonstrated as soon as 30 minutes after dosing for 100 mg...